Hugel, Inc. develops and manufactures biopharmaceuticals in South Korea and internationally. The company offers Botulinum Toxin, a white injectable dry powder in a transparent glass vial for use in the treatment of positive essential eyelid convulsion in adults over 18 years of age; improvement of severe lasso wrinkles associated with corrugator muscles and/or procerus muscle activities in adults aged between 18 and 65; treatment of upper limb stroke; and treatment of dynamic equinus foot deformity in children with cerebral palsy over 2 years of age, as well as improvement of external angles of secondary ideals related to orbicularis oculi muscle activity in adults aged between 19 and 65 under the Botulax, Regenox, Zentox, Reage, Magnion, Hugel Toxin, Juvenlife, Botulim, and Botoshot brands. It also provides hyaluronic acid filler under the Dermalax, and The Chaeum brand names; cosmetics under the Wellage brand; and medical devices under BlueRose brand name. Hugel, Inc. was founded in 2001 and is headquartered in Chuncheon-si, South Korea.
Frequently asked questions
What sector does Hugel Inc (145020) operate in?
Hugel Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Hugel Inc (145020) current stock price?
As of the latest data, Hugel Inc stock price is ₩262,500, with a previous close of ₩268,500. Hugel Inc lost -₩6,000 in the last trading session, representing a -2.23% loss.
What is Hugel Inc (145020) current market capitalization?
Hugel Inc market cap is approximately 2.84 trillion.
Does Hugel Inc (145020) pay dividends?
No. Hugel Inc does not pay a dividend.
How did Hugel Inc (145020) perform in its most recent earnings report?
In the last report (March 31, 2026), Hugel Inc posted an EPS surprise of 52.51% and a revenue surprise of 7.94%.
When is Hugel Inc (145020) next earnings report?
Hugel Inc is expected to release its next earnings report on June 30, 2026.
What is Hugel Inc (145020) beta (volatility) score?
Hugel Inc has a beta of 0.533, indicating lower volatility than the overall market.
